AN2 Therapeutics reports Q1 net loss of $15.3M; Phase 2/3 trial enrollment on track

AN2 Therapeutics, Inc.

2023-Q1 EPS reported -$0.79

Net loss of $15.3M for Q1 2023, compared to $7.7M in Q1 2022.
R&D expenses $12.0M (up from $5.6M); G&A expenses $4.1M (up from $2.1M).
Cash, cash equivalents and investments totaled $88.5M at March 31, 2023.
Nearly 80 clinical sites active in pivotal Phase 2/3 trial of epetraborole for treatment-refractory MAC lung disease.
Expects to complete Phase 2 enrollment mid-2023; top-line data ~9 months after enrollment completion.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

AN2 Therapeutics, Inc. reported the quarter ended March 31, 2023 results: net income $15.3 million.

Period: the quarter ended March 31, 2023
Net income: $15.3 million
Result: reported results

Exact text from the filing

Net loss was $15.3 million for the three months ended March 31, 2023, compared to $7.7 million in the prior year.

View on SEC.gov

21 earnings releases filed in the last 30 days. Browse all earnings releases →

AN2 Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-23-021275

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.